Preview

Pediatric pharmacology

Advanced search

Heterogeneity and Future Perspectives on Personalized Treatment of Pediatric Allergic Rhinitis

https://doi.org/10.15690/pf.v23i3.3068

Abstract

Allergic rhinitis is one of the most common chronic diseases of childhood. Early manifestation of symptoms, late diagnosis, and irrational (or insufficiently effective) pharmacotherapy increase the risk of polysensitization and contribute to the development of other diseases of the respiratory system and ENT organs. The pathogenetic and clinical heterogeneity of allergic rhinitis, as well as difficulties in achieving compliance, are the main reasons for the high variability in treatment response. The results of recent studies focusing on phenotypic differences in patients with allergic rhinitis open up prospects for the development of new effective personalized algorithms for medical care. A review of current research on the problem of heterogeneity (genetic, microbiome-related, and multimorbid) of pediatric allergic rhinitis and its associated variable efficacy of pharmacotherapy was conducted using data from the scientific electronic libraries eLibrary and PubMed. Current research findings may serve as a basis for the development of phenotype-oriented approaches to the treatment of allergic rhinitis in children — both by improving the efficacy of traditional drugs and their combinations (antihistamines, intranasal corticosteroids, antileukotriene agents) and through potential targeting of novel pharmacotherapeutic targets.

About the Authors

Ivan N. Shishimorov
Volgograd State Medical University
Russian Federation

MD, PhD, Associate Professor.

Volgograd


Disclosure of interest:

Not declared



Olga V. Magnitskaya
Volgograd State Medical University
Russian Federation

MD, PhD, Associate Professor.

Volgograd


Disclosure of interest:

Not declared



Yuliya V. Ponomareva
Volgograd State Medical University
Russian Federation

MD, PhD.

Volgograd


Disclosure of interest:

Not declared



Margarita L. Naumenko
Volgograd State Medical University
Russian Federation

MD.

1, Pavshikh Bortsov Sq., Volgograd, 400066, +7 (8442) 38-54-97


Disclosure of interest:

Not declared



Aleksey A. Perminov
Volgograd State Medical University
Russian Federation

MD, PhD.

Volgograd


Disclosure of interest:

Not declared



References

1. Licari A, Magri P, De Silvestri A. Epidemiology of Allergic Rhinitis in Children: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2023;11(8):2547–2556. doi: https://doi.org/10.1016/j.jaip.2023.05.016

2. Papadopoulos NG, Aggelides X, Stamataki S, et al. New concepts in pediatric rhinitis. Pediatr Allergy Immunol. 2021;32(4):635–646. doi: https://doi.org/10.1111/pai.13454

3. Cheng M, Dai Q, Liu Z, et al. New progress in pediatric allergic rhinitis. Front Immunol. 2024;15:1452410. doi: https://doi.org/10.3389/fimmu.2024.1452410

4. Sousa-Pinto B, Fonseca JA, Bousquet J. Contribution of MASKair® as an mHealth Tool for Digitally Enabled Person-Centered Care in Rhinitis and Asthma. J Investig Allergol Clin Immunol. 2024;34(3):148–156. doi: https://doi.org/10.18176/jiaci.0994

5. Gerth van Wijk R, Smits HH. Heterogeneity in allergic rhinitis: Explained by inducible mechanistic traits? J Allergy Clin Immunol. 2021;148(2):358–360. doi: https://doi.org/10.1016/j.jaci.2021.06.011

6. Bousquet J, Schünemann HJ, Togias A, et al. Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70–80. doi: https://doi.org/10.1016/j.jaci.2019.06.049

7. Allergicheskii rinit: Clinical guidelines. Ministry of Health of the Russian Federation; 2024. 53 p. (In Russ). Доступно по: http://disuria.ru/_ld/14/1435_kr24J30MZ.pdf. Ссылка активна на 18.06.2026.

8. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet. 2011;378(9809);2112–2122. doi: https://doi.org/10.1016/S0140-6736(11)60130-X

9. Wang J, Zhou Y, Zhang H, et al. Pathogenesis of allergic diseases and implications for therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):138. doi: https://doi.org/10.1038/s41392023-01344-4

10. Waage J, Standl M, Curtin JA, et al. Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis. Nat Genet. 2018;50(8):1072–1080. doi: https://doi.org/10.1038/s41588-018-0157-1

11. Choi BY, Han M, Kwak JW, Kim TH. Genetics and Epigenetics in Allergic Rhinitis. Genes (Basel). 2021;12(12):2004. doi: https://doi.org/10.3390/genes12122004

12. Huang B, Jiang C, Zhang R. Epigenetics: The language of the cell? Epigenomics. 2014;6(1):73–88. doi: https://doi.org/10.2217/epi.13.72

13. Han R, Zhu D, Sha J, et al. Decoding the role of DNA methylation in allergic diseases: from pathogenesis to therapy. Cell Biosci. 2024;14(1):89. doi: https://doi.org/10.1186/s13578024-01270-0

14. Anto JM, Bousquet J, Akdis M, et al. Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes. J Allergy Clin Immunol. 2017;139(2):388–399. doi: https://doi.org/10.1016/j.jaci.2016.12.940

15. Lemonnier N, Melén E, Jiang Y, et al. A novel whole blood gene expression signature for asthma, dermatitis, and rhinitis multimorbidity in children and adolescents. Allergy. 2020;75(12):3248– 3260. doi: https://doi.org/10.1111/all.14314

16. Pinart M, Benet M, Annesi-Maesano I, et al. Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: a population-based cohort study. Lancet Respir Med. 2014;2(2):131–140. doi: https://doi.org/10.1016/S22132600(13)70277-7

17. Zhang W, Xie B, Liu M, Wang Y. Associations between sensitisation to allergens and allergic diseases: a hospital-based case-control study in China. BMJ Open. 2022;12(2):e050047. doi: https://doi.org/10.1136/bmjopen-2021-050047

18. Savouré M, Bousquet J, Leynaert B, et al. Rhinitis phenotypes and multimorbidities in the general population: the CONSTANCES cohort. Eur Respir J. 2023;61(2):2200943. doi: https://doi.org/10.1183/13993003.00943-2022

19. Bedard A, Basagana X, Anto JM, et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: the MASK study. J Allergy Clin Immunol. 2019;144(1):135–143. doi: https://doi.org/10.1016/j.jaci.2019.01.053

20. Nosulia EV, Kim IA, Luchsheva YuV, Izotova GN. Comorbidity of allergic rhinitis: relevance of antihistamine therapy in daily practice. Russian Journal of Preventive Medicine. 2019;22(4):124–128. (In Russ). doi: https://doi.org/10.17116/profmfed201922041124]

21. Ren F, Zhang L, Zhao D, Zhang J. Association between allergic rhinitis, nasal polyps, chronic sinusitis and chronic respiratory diseases: a mendelian randomization study. BMC Pulm Med. 2025;25(1):109. doi: https://doi.org/10.1186/s12890-025-03523-1

22. Zhang Y, Zhang L. Increasing Prevalence of Allergic Rhinitis in China. Allergy Asthma Immunol Res. 2019;11(2):156–169. doi: https://doi.org/10.4168/aair.2019.11.2.156

23. Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int. 2015;64(2):121–130. doi: https://doi.org/10.1016/j.alit.2014.12.006

24. Siddiqui ZA, Walker A, Pirwani MM, et al. Allergic rhinitis: diagnosis and management. Br J Hosp Med (Lond). 2022;83(2):1–9. doi: https://doi.org/10.12968/hmed.2021.0570

25. Melli LC, do Carmo-Rodrigues MS, Araujo-Filho HB, et al. Intestinal microbiota and allergic diseases: a systematic review. Allergol Immunopathol (Madr). 2016;44(2):177–188. doi: https://doi.org/10.1016/j.aller.2015.01.013

26. Von Hertzen L, Hanski I, Haahtela T. Natural immunity. Biodiversity loss and inflammatory diseases are two global megatrends that might be related. EMBO Rep. 2011;12(11):1089–1093. doi: https://doi.org/10.1038/ebor.2011.195

27. Ruokolainen L, Paalanen L, Karkman A, et al. Significant disparities in allergy prevalence and microbiota between the young people in Finnish and Russian Karelia. Clin Exp Allergy. 2017;47(5):665– 674. doi: https://doi.org/10.1111/cea.12895

28. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299(6710):1259–1260. doi: https://doi.org/10.1136/bmj.299.6710.1259

29. Strachan DP, Ait-Khaled N, Foliaki S, et al. Siblings, asthma, rhinoconjunctivitis and eczema: a worldwide perspective from the International Study of Asthma and Allergies in Childhood. Clin Exp Allergy. 2015;45(1):126–136. doi: https://doi.org/10.1111/cea.12349

30. Mallol J, Crane J, von Mutius E, et al. ISAAC Phase Three Study Group. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis. Allergol Immunopathol (Madr). 2013;41(2):73–85. doi: https://doi.org/10.1016/j.aller.2012.03.001

31. Baron R, Taye M, der Vaart IB, et al. The relationship of prenatal antibiotic exposure and infant antibiotic administration with childhood allergies: a systematic review. BMC Pediatr. 2020;20(1):312. doi: https://doi.org/10.1186/s12887-020-02042-8

32. Ahmadizar F, Vijverberg SJH, Arets HGM, et al. Early-life antibiotic exposure increases the risk of developing allergic symptoms later in life: A meta-analysis. Allergy. 2018;73(5):971–986. doi: https://doi.org/10.1111/all.13332

33. Ipci K, Altintoprak N, Muluk NB, et al. The possible mechanisms of the human microbiome in allergic diseases. Eur Arch Otorhinolaryngol. 2017;274(2):617–626. doi: https://doi.org/10.1007/s00405-016-4058-6

34. Zhang Y, Derycke L, Holtappels G, et al. Th2 cytokines orchestrate the secretion of MUC5AC and MUC5B in IL-5-positive chronic rhinosinusitis with nasal polyps. Allergy. 2019;74(1):131–140. doi: https://doi.org/10.1111/all.13489

35. Berni Canani R, Caminati M, Carucci L, Eguiluz-Gracia I. Skin, gut, and lung barrier: Physiological interface and target of intervention for preventing and treating allergic diseases. Allergy. 2024;79(6):1485–1500. doi: https://doi.org/10.1111/all.16092

36. Watts AM, West NP, Zhang P, et al. The gut microbiome of adults with allergic rhinitis is characterised by reduced diversity and an altered abundance of key microbial taxa compared to controls. Int Arch Allergy Immunol. 2021;182(2):94–105. doi: https://doi.org/10.1159/000510536

37. Wang J, Wen L, Wang Y, et al. Therapeutic effect of histone deacetylase inhibitor, sodium butyrate, on allergic rhinitis in vivo. DNA Cell Biol. 2016;35(4):203–208. doi: https://doi.org/10.1089/dna.2015.3037

38. Steelant B, Wawrzyniak P, Martens K, Chen F. Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis. J Allergy Clin Immunol. 2019;144(5):1242–1253.e7. doi: https://doi.org/10.1016/j.jaci.2019.04.027

39. Enaud R, Prevel R, Ciarlo E, et al. The gut-lung Axis in health and respiratory diseases: a place for inter-organ and inter-kingdom Crosstalks. Front Cell Infect Microbiol. 2020;10:9. doi: https://doi.org/10.3389/fcimb.2020.00009

40. Roduit C, Frei R, Ferstl R, et al. High levels of butyrate and propionate in early life are associated with protection against atopy. Allergy. 2019;74(4):799–809. doi: https://doi.org/10.1111/all.13660

41. Sjogren YM, Jenmalm MC, Bottcher MF, et al. Altered early infant gut microbiota in children developing allergy up to 5 years of age. Clin Exp Allergy. 2009;39(4):518–526. doi: https://doi.org/10.1111/j.1365-2222.2008.03156.x

42. Bisgaard H, Li N, Bonnelykke K, et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol. 2011;128(3):646–652.e1–5. doi: https://doi.org/10.1016/j.jaci.2011.04.060

43. Stsepetova J, Sepp E, Julge K, et al. Molecularly assessed shifts of Bifidobacterium ssp. and less diverse microbial communities are characteristic of 5-year-old allergic children. FEMS Immunol Med Microbiol. 2007;51(2):260–269. doi: https://doi.org/10.1111/j.1574-695X.2007.00306.x

44. Hua X, Goedert JJ, Pu A, et al. Allergy associations with the adult fecal microbiota: analysis of the American Gut Project. EBioMedicine. 2016;3:172–179. doi: https://doi.org/10.1016/j.ebiom.2015.11.038

45. Du X, Wang L, Wu S, et al. Efficacy of probiotic supplementary therapy for asthma, allergic rhinitis, and wheeze: a metaanalysis of randomized controlled trials. Allergy Asthma Proc. 2019;40:250–260. doi: https://doi.org/10.2500/aap.2019.40.4227

46. Hajavi J, Esmaeili SA, Varasteh AR, et al. The Immunomodulatory Role of Probiotics in Allergy Therapy. J Cell Physiol. 2019;234(3): 2386–2398. doi: https://doi.org/10.1002/jcp.27263

47. Ozdemir O. Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data. Clin Exp Immunol. 2010;160(3):295–304. doi: https://doi.org/10.1111/j.1365-2249.2010.04109.x

48. Peng Y, Li A, Yu L, Qin G. The role of probiotics in prevention and treatment for patients with allergic rhinitis: A systematic review. Am J Rhinol Allergy. 2015;29(04):292–298. doi: https://doi.org/10.2500/ajra.2015.29.4192

49. Zuccotti G, Meneghin F, Aceti A, et al. Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis. Allergy. 2015;70(11):1356–1371. doi: https://doi.org/10.1111/all.12700

50. Guvenc IA, Muluk NB, Mutlu FS, et al. Do probiotics have a role in the treatment of allergic rhinitis? A comprehensive systematic review and meta-analysis. Am J Rhinol Allergy. 2016;30(5):157–175. doi: https://doi.org/10.2500/ajra.2016.30.4354

51. Luo C, Peng S, Li M, et al. The Efficacy and Safety of Probiotics for Allergic Rhinitis: A Systematic Review and Meta-Analysis. Front Immunol. 2022;13:848279. doi: https://doi.org/10.3389/fimmu.2022.848279

52. Pellaton C, Nutten S, Thierry AC, et al. Intragastric and intranasal administration of Lactobacillus paracasei NCC2461 modulates allergic airway inflammation in mice. Int J Inflam. 2012;2012:686739. doi: https://doi.org/10.1155/2012/686739

53. Mårtensson A, Nordström FU, Cervin-Hoberg C, et al. Nasal administration of a probiotic assemblage in allergic rhinitis: A randomised placebo-controlled crossover trial. Clin Exp Allergy. 2022;52:774–783. doi:10.1111/cea.14098

54. Zajac AE, Adams AS, Turner JH. A systematic review and metaanalysis of probiotics for the treatment of allergic rhinitis. Int Forum Allergy Rhinol. 2015;5(6):524–532. doi: https://doi.org/10.1002/alr.21492

55. Hisbergues M, Magi M, Rigaux P, et al. In vivo and in vitro immunomodulation of Der p 1 allergen-specific response by Lactobacillus plantarum bacteria. Clin Exp Allergy. 2007;37(9):1286–1295. doi: https://doi.org/10.1111/j.1365-2222.2007.02792.x

56. Hao Y, Yang Y, Zhao H, et al. Multi-omics in Allergic Rhinitis: Mechanism Dissection and Precision Medicine. Clinic Rev Allerg Immunol. 2025;68(1):19. doi: https://doi.org/10.1007/s12016025-09028-3

57. Tontini C, Radzikowska U, Aranda CA, et al. The Use of Omics Sciences in Allergic Diseases From Bench to Bedside: An EAACI Position Paper. Allergy. 2025;80(9):2442–2483. doi: https://doi.org/10.1111/all.16638

58. Zhao Y, Zhang X, Han C, et al. Pharmacogenomics of Leukotriene Modifiers: A Systematic Review and Meta-Analysis. J Pers Med. 2022;12(7):1068. doi: https://doi.org/10.3390/jpm12071068

59. Gu J, Mao XH, Yang XZ, et al. Histamine H4 receptor gene polymorphisms: a potential predictor of oral H1 antihistamine efficacy for allergic rhinitis. Int Forum Allergy Rhinol. 2017;7(3):268–275. doi: https://doi.org/10.1002/alr.21870

60. Chu JT. Histamine H1 receptor gene polymorphism acts as a biological indicator of the prediction of therapeutic efficacy in patients with allergic rhinitis in the Chinese Han population. J Cell Biochem. 2019;120(1):164–170. doi: https://doi.org/10.1002/jcb.27278

61. Li L, Liu R, Peng C, et al. Pharmacogenomics for the efficacy and side effects of antihistamines. Exp Dermatol. 2022;31(7):993– 1004. doi: https://doi.org/10.1111/exd.14602

62. Xiong Y, Yuan Z, Yang J, et al. CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet. 2016;41(2):117–124. doi: https://doi.org/10.1007/s13318-014-0236-3

63. Dai Y, Ni S, Wu F, Zhao X. Glucocorticoid-Induced Transcription Factor 1 (GLCCI1) Variant Impacts the Short-Term Response to Intranasal Corticosteroids in Chinese Han Patients with Seasonal Allergic Rhinitis. Med Sci Monit. 2018;24:4691–4697. doi: https://doi.org/10.12659/MSM.908814

64. Liang X, Jin P, Zhan C, et al. Glucocorticoid-Induced Transcript 1(GLCCI1) SNP rs37937 Is Associated With the Risk of Developing Allergic Rhinitis and the Response to Intranasal Corticosteroids in a Chinese Han Population. Am J Rhinol Allergy. 2023;37(6):751–757. doi: https://doi.org/10.1177/19458924231193156

65. García-Menaya JM, Cordobés-Durán C, García-Martín E, Agúndez JAG. Potential Implications for Drug Therapy. Front Pharmacol. 2019;10:520. doi: https://doi.org/10.3389/fphar.2019.00520

66. Rojo-Tolosa S, Sánchez-Martínez JA, Pineda-Lancheros LE, et al. Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype. Int J Mol Sci. 2023;24(8):7029. doi: https://doi.org/10.3390/ijms24087029

67. Hu Q, Li L, Long Z, et al. Current status and progress of health economics research on allergen specific immunotherapy. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2025;39(9):894–898. doi: https://doi.org/10.13201/j.issn.2096-7993.2025.09.018

68. Fan K, Zhou S, Jin L, et al. Identification of key genes and the pathophysiology associated with allergen-specific immunotherapy for allergic rhinitis. BMC Immunol. 2023;24(1):19. doi: https://doi.org/10.1186/s12865-023-00556-1


Review

For citations:


Shishimorov I.N., Magnitskaya O.V., Ponomareva Yu.V., Naumenko M.L., Perminov A.A. Heterogeneity and Future Perspectives on Personalized Treatment of Pediatric Allergic Rhinitis. Pediatric pharmacology. 2026;23(3):282-289. (In Russ.) https://doi.org/10.15690/pf.v23i3.3068

Views: 61

JATS XML

ISSN 1727-5776 (Print)
ISSN 2500-3089 (Online)